EXELIXIS INC. overview

Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor PR Newswire ALAMEDA, Calif. and NEW YORK, Sept. 13, 2023 — ISM3091 is a highly selective, orally bioavailable small molecule inhibitor of USP1 identified through Insilico Medicine's artificial intelligence (AI) platform, with potent activity in BRCA-mutated tumor models — — In May 2023 , the U.S. Food and Drug Administration (FDA) cleared Insilico's...

Exelixis, Inc. (Nasdaq: EXEL) and Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the global phase 3 CONTACT-02 pivotal trial met one of two primary endpoints, demonstrating a statistically significant improvement in progression-free survival (PFS) at the primary analysis. CONTACT-02 is evaluating cabozantinib (CABOMETYX ® ) in combination with atezolizumab compared with a second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) and...

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2023 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones. “In the second quarter of 2023, the Exelixis team continued to make steady progress both on our commercial business and our rapidly advancing pipeline,” said Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis. “It was another...

Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into a Settlement and License Agreement (Agreement) with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (collectively Teva). This settlement resolves patent litigation brought by Exelixis in response to Teva’s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of CABOMETYX ® (cabozantinib) tablets prior to the expiration of the applicable patents. Pursuant to the...

Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2023 financial results will be released on Tuesday, August 1, 2023 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company’s website. To access the conference call, please register using this link . Upon registration, a dial-in number and...

Farallon Capital Management, L.L.C. (“Farallon”) manages funds that own approximately 7.8% of the outstanding shares of Exelixis, Inc. (NASDAQ: EXEL) (“Exelixis” or the “Company”), making it the Company’s largest active shareholder. Farallon today commented on the preliminary results of Exelixis’ 2023 Annual Meeting of Shareholders (the “Annual Meeting”), including the election to the Board of Directors (the “Board”) of all three Farallon director candidates: Tom Heyman,...

Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in June: William Blair 43 rd Annual Growth Stock Conference: Exelixis is scheduled to present at 10:20 am ET / 9:20 am CT/ 7:20 am PT on Tuesday, June 6 in Chicago. 2023 Jefferies Global Healthcare Conference: Exelixis is scheduled to present at 10:30 am ET/ 7:30 am PT on Wednesday, June 7 in New York. Goldman Sachs 44 th Annual...

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2023 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones. “The Exelixis team continued to execute on our key priorities and made significant progress in advancing our commercial business and our growing pipeline,” said Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis. “CABOMETYX ®...